Timing clarification: Axon is scheduled to report today, Wednesday, August 5, 2026, after the market closes—not tomorrow. The earnings call begins at 5:00 p.m. ET. (investor.axon.com)
Axon enters Q2 with unusually strong operating momentum—and a demanding setup.
The company began 2026 with revenue growth of 34%, accelerating adoption of its AI products, triple-digit growth at Dedrone, and strength across international and enterprise customers. Management raised full-year revenue guidance after Q1 while maintaining its 25.5% adjusted EBITDA-margin target. (sec.gov)
The issue is not whether Axon is growing. It is whether the report can clear expectations that have risen alongside the stock. AXON closed August 4 at $607.24, up roughly 57% since the Q1 report and 5% on the session immediately preceding earnings. At that price, the shares trade at approximately 14 times estimated 2026 enterprise value/revenue. A merely in-line quarter could therefore be insufficient.
The central question: Can AI, counter-drone and international growth sustain revenue above 30% without further eroding gross margin or delaying free-cash-flow conversion?
| Metric | Q2 2026 consensus | Q2 2025 actual | Implied change |
|---|---|---|---|
| Revenue | $876.5M | $668.5M | +31.1% |
| Adjusted EPS | $1.83 | $2.12 | Down YoY |
| Current FY26 revenue guidance | 30%–32% growth | — | Approximately $3.61B–$3.67B |
| Current FY26 adjusted EBITDA margin target | 25.5% | — | Unchanged after Q1 |
Consensus data are approximately $876.46 million of revenue and $1.83 of EPS. (investing.com)
EPS is likely to be a secondary indicator because Axon’s GAAP and non-GAAP earnings can be affected by stock compensation, investment marks, taxes and acquisition-related items. Revenue, adjusted EBITDA, bookings and forward guidance should matter more.
Consensus already assumes 31% growth, close to the midpoint of management’s full-year range. Axon has also beaten revenue expectations in each of the past four quarters, so investors are conditioned to expect upside. (investing.com)
A strong print would likely mean:
Current guidance implies approximately $3.61 billion to $3.67 billion of 2026 revenue. Assuming consensus Q2 revenue, Axon would need Q3 and Q4 to average roughly $965 million to $993 million each. That is achievable given normal second-half seasonality, but it leaves management dependent on continued large deployments and timely hardware shipments.
Q1 AI-product revenue grew more than 700%, albeit from a small base, while AI bookings rose 140%. Management said nearly all large U.S. law-enforcement agencies were including AI in new purchases. The AI Era Plan is also helping Axon reopen existing customer contracts before their scheduled expiration.
Investors should look for:
The key operating metrics are annual recurring revenue and net revenue retention. Q1 ARR was $1.49 billion, up 35%, and NRR was 125%. (sec.gov) A strong Q2 would keep ARR growth near or above 35% and NRR around 125%.
A drop in NRR toward 120% would not break the thesis, but it would weaken the argument that AI-driven expansion is accelerating.
Dedrone revenue grew more than 300% in Q1, while management said bookings increased about 500%. Counter-drone demand is opening doors across state and local government, federal agencies, international customers and enterprise security.
Management also indicated that product availability—not demand—was the principal near-term constraint.
That creates several questions for Q2:
Dedrone is strategically valuable but currently dilutive to Connected Devices margins. Q1 adjusted Connected Devices gross margin fell 240 basis points year over year to 50.4%, reflecting tariffs and increased Dedrone mix. (sec.gov)
Investors should tolerate some gross-margin pressure if Dedrone bookings remain exceptional. The less favorable outcome would be lower margins without continued acceleration in bookings or revenue.
International revenue more than doubled in Q1 and represented 20% of company revenue, compared with 12% one year earlier. Management attributed the strength to improved go-to-market execution, broader cloud acceptance and Dedrone-led opportunities.
International sales can be lumpy because national deployments and hardware orders are large. Still, another quarter around 20% of revenue would support the view that Axon has developed a durable second growth engine beyond U.S. state and local law enforcement.
Important commentary will include:
Q1 adjusted EBITDA was $202 million, or 25.0% of revenue. Management reiterated a 25.5% full-year margin and said operating leverage should improve during the second half. (sec.gov)
The margin puts and takes are straightforward:
Positive
Negative
An adjusted EBITDA margin around 25%–26% would be healthy. More important than a few basis points in Q2 is whether management remains confident in 25.5% for the year while sustaining 30%-plus revenue growth.
A guide that sacrifices margin to fund unexpectedly stronger demand could be defensible. A margin reduction caused by tariffs, services costs or acquisition integration would be less favorably received.
Q1 free cash flow was negative $55 million, primarily because of normal seasonal payments and inventory investment. Management nevertheless maintained expectations for approximately $450 million of full-year free cash flow and more than $600 million of operating cash flow. (sec.gov)
That implies a substantial cash-generation ramp during the remaining three quarters.
Watch:
Inventory investment is not necessarily negative: management deliberately built supply to avoid constraining Dedrone, TASER, camera and international growth. But investors need evidence that inventory is converting into shipments and cash rather than continuing to accumulate.
Several businesses are unlikely to be individually material to Q2 revenue but could affect the longer-term narrative:
These initiatives matter less for the immediate consensus beat than for confidence in Axon’s 2028 targets.
Axon raised its 2026 revenue-growth outlook after Q1 from 27%–30% to 30%–32%, while retaining the 25.5% adjusted EBITDA-margin target. (sec.gov)
Given the stock’s pre-earnings rally, the likely market thresholds are:
At the August 4 close, AXON’s implied enterprise value is roughly $51 billion, using Q1 net debt and diluted shares. That is around 14 times the midpoint of current 2026 revenue guidance.
The valuation reflects more than one strong year. Axon is targeting approximately $6 billion of revenue and a 28% adjusted EBITDA margin in 2028. Reaching that target from the midpoint of 2026 guidance requires roughly 28% annual revenue growth in both 2027 and 2028.
That is an exceptional trajectory for a company already approaching $4 billion in annual sales. This quarter therefore needs to support not only 2026 estimates but the durability of growth through 2028.
Stock-based compensation also remains relevant. Axon expects $590 million–$620 million of SBC in 2026 while targeting average annual dilution below 2.5%. Investors may accept high SBC while revenue compounds above 30%, but the debate will intensify if growth moderates without a corresponding improvement in GAAP profitability and cash conversion.
Axon’s fundamentals going into Q2 appear strong: core TASER and body-camera demand remains healthy, software expansion is supporting 125% NRR, AI adoption is accelerating, and Dedrone has emerged as a potentially significant new growth engine.
But the stock now demands a correspondingly strong report. With consensus already calling for approximately 31% revenue growth and shares up sharply since Q1, the likely hurdle is a beat-and-raise accompanied by stable margins and convincing cash-flow commentary.
The highest-quality result would show that AI and counter-drone growth are not isolated bursts: they are increasing recurring revenue, expanding bookings, opening international and enterprise accounts, and doing so without undermining Axon’s 25.5% profitability framework.